Related Experiment Videos
Hydroxyurea in the management of therapy resistant psoriasis
A M Layton1, R A Sheehan-Dare, M J Goodfield
1Department of Dermatology, General Infirmary, Leeds, U.K.
The British Journal of Dermatology
|November 1, 1989
Summary
Hydroxyurea effectively treats chronic plaque psoriasis unresponsive to topical therapies, with 61% achieving remission. While some adverse effects occurred, serious complications were rare, suggesting a favorable safety profile compared to other cytotoxic drugs.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Chronic plaque psoriasis is a challenging skin condition.
- Many patients do not respond to conventional topical treatments.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of hydroxyurea for psoriasis.
- To compare hydroxyurea's adverse effects with other cytotoxic drugs.
Main Methods:
- Eighty-five patients with extensive chronic plaque psoriasis were treated with hydroxyurea (0.5-1.5 g daily).
- Treatment duration was long-term.
- Efficacy and adverse events were monitored.
Main Results:
- 61% of patients achieved satisfactory remission.
- Treatment was discontinued in 39% due to inadequate response or adverse reactions.
- Hematological abnormalities occurred in 35% but were manageable.
- Actinic psoriasis developed in 4.7% of patients.
Conclusions:
- Hydroxyurea is an effective long-term treatment for refractory chronic plaque psoriasis.
- Its incidence of serious adverse effects is favorable compared to other cytotoxic drugs.